Original articleRisk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis
Introduction
The spectrum of therapeutic strategies for chronic IRD, mainly RA and spondyloarthritis, is increasing. In particular, a better understanding of the pathogenesis of these diseases has led to new-targeted treatments. The most widely used, TNF blockers, are highly efficient in patients with IRD that cannot be controlled with conventional DMARDs. However, the drugs have side effects, in particular increased risk of infection. The overall rate of severe infections with TNF blockers is estimated at about five PY upon 100, mainly related to bacterial agents [1], [2].
The risk of infection with TNF blockers has received much interest, with many studies or meta-analyses conducted on the topic. Initially, opportunistic infection, including granulomatosis infection, such as tuberculosis, was reported in patients receiving TNF blockers [3]. However, we lack data on risk of viral infection, especially that due to herpes species, in patients with IRD receiving anti-TNF drugs. Although herpes infection is frequent and often trivialized, there are severe forms such as HZ multidermatomal forms or those requiring hospitalization or intravenous treatment in patients receiving biologics [4]. Known risk factors for HZ are especially older age and immunosuppressive therapy [5], [6]. In fact, herpes virus infections, especially with HZ, exhibit reactivation of latent VZV infection and can cause substantial mortality among elderly and immunodeficient patients. The risk of HZ clearly increases in a very non-liner manner with increasing age, with a dramatically higher susceptibility to this reactivation in elderly people. The most common complications are bacterial secondary infection and post-herpetic neuralgia.
We aimed to assess the safety of TNF blockers in terms of HZ in patients with RA by a meta-analysis of data from observational registries or RCTs. The primary objective was the analysis of an association of RA treated with TNF blockers as compared with conventional DMARDs and risk of HZ.
Section snippets
Data retrieval
We systematically searched the literature for articles reporting herpes virus infection in patients with IRD receiving TNF blockers that were published in English or French up to March 2013 in MEDLINE via PubMED, EMBASE, Cochrane library databases, and American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) abstracts (from 2008 to 2011). Search keywords were (immunosuppressive agents [Mesh] OR antirheumatic agents [Mesh] OR infliximab [substance name] OR adalimumab
Literature search
The literature search identified 3446 articles and 88 congress abstracts, from which 28 were considered relevant for the present study. The manual search of registries retrieved seven additional articles. Finally, 26 articles and nine abstracts were included in the study (Fig. 1). Reasons for exclusion were especially treatment different from TNF-blockers, disease of interest different from IRD, no quantitative data about HZ incidence or case reports. Among included publications, six articles
Discussion
To our knowledge, this is the first study to estimate, by pooled RR, the relative risk of HZ for patients with RA receiving TNF blockers in comparison with conventional DMARDs.
Several points were highlighted by our meta-analysis and systematic review of literature.
With data from seven registries, the pooled risk of HZ with TNF blockers was estimated significantly increased, up to 61%.
The annualized incidence of HZ is about three cases per 1000 PY in large general population-based studies and
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
Acknowledgments
Abbott France pharmaceutical company provided logistic support by organizing a meta-analysis methods workshop but played no further role in the project.
References (37)
- et al.
What does epidemiology tell us about risk factors for herpes zoster?
Lancet Infect Dis
(2004) The risk of infections with biologic therapies for rheumatoid arthritis. Semin
Arthritis Rheum
(2010)- et al.
Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry
J Invest Dermatol
(2012) - et al.
Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes
J Investig Dermatol Symp Proc
(2007) - et al.
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases
JAMA
(2012) - et al.
Infections in patients with rheumatoid arthritis treated with biologic agents
Arthritis Rheum
(2005) - et al.
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
Rheumatology (Oxford)
(2011) - et al.
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
JAMA
(2006) - et al.
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
Ann Rheum Dis
(2013) Aging, immunity, and the varicella-zoster virus
N Engl J Med
(2005)
Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis
Clin Infect Dis
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents
JAMA
Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
Ann Rheum Dis
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster
JAMA
Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis
Arthritis Care Res
Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort
Ann Rheum Dis
Biologic register in a developing country: safety is different from european registries? The biobadabrasil first results
Ann Rheum Dis
Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis
Rheumatol Int
Cited by (76)
Vaccinations and Biologics
2020, Infectious Disease Clinics of North AmericaCan patients on methotrexate receive live vaccines?
2019, Revue du Rhumatisme (Edition Francaise)Can patients on methotrexate receive live vaccines?
2019, Joint Bone Spine